AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03977571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tissue sampling
Description: Tumor biopsies, blood, and stool specimens for translational biomarker research will be sampled at baseline and after 3 or 6 months.
Study NCT03977571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Tissue sampling
Description: Tumor biopsies, blood, and stool specimens for translational biomarker research will be sampled at baseline and after 3 or 6 months.
Study NCT03299127 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: imagery rescripting
Description: The long version of the manual contained 4,959 words, the brief version had 3,369 words. Individuals were encouraged patients to time travel to negative personal events, enter the scene and protect or comfort their younger-ego. The participant should bring the negative event to a happy end. This could also be a fictive, compassionate person and may violate the laws of physics (e.g., a person may fly). Readers were encouraged to embellish the scenes as much as possible so that it competed with the original scene. This technique was then applied to future events. For the last technique, patients were asked to seek a corresponding mood-congruent metaphor, creature or symbol; for example, a small bird that has fallen out of its nest. Using their mind's eye, these images may be transformed into something of beauty or pride.
Study NCT01951378 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Hudson RCI® nebulizer
Description: After the first hour of treatment, patients in the standard arm will receive a repeat assessment, including all of the measurements collected at baseline as well as reported side effects. Those patients who score PAS 0-2 will then be discharged home, after an optional observation period, as per the pathway. Those who score PAS > 2 will receive a second treatment. At the end of the second treatment patients will again be re-assessed, and repeat measurements obtained. At that time, depending on the patient's PAS score, he/she will be dispositioned to home, the floor, the pulmonary high acuity unit (PHAU), or the pediatric intensive care unit (PICU).
Study NCT01951378 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: NebuTech® HDN® nebulizer
Description: All treatments in the NebuTech® arm will be given at a standard dilution of 5 ml (diluted with normal saline to a total volume of 5 ml as per the manufacturer's recommendation). Patients in this arm will receive up to four treatments with parameters measured after each treatment, similar to the control arm. Patients who complete four treatments will then be dispositioned based on PAS score, similar to the control arm. Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
Study NCT01951378 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albuterol
Description: Subjects may have started treatment prior to consent and may receives unit dose (2.5 mg) Albuterol/Proventil treatments will be given with a standard nebulizer up to 3 times as needed and may change over to study randomized device once consented to eith arm.
Study NCT05019313 — intervention group
Intervention type: DEVICE
Intervention: Evaluation of diaphragmatic contractility by ultrasound
Description: Lung ultrasound is performed during mechanical ventilation weaning. The diaphragmatic thickening fraction is evaluated positioning a linear probe in midaxillary line. Inspiratory and expiratory measurements are bilateral and are M-mode images. Right diaphragmatic thickening fraction has been considered as true and reproducible measurement.
Study NCT02624869 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Evolocumab
Description: Administered by subcutaneous injection
Study NCT02813213 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Skin micro Grafts
Description: 0.8 x 0.8 skin micro graft with graft to graft distance of 4 cm (1:50 expansion) bathed with keratinocyte growth factor solution ( 1.5 ml for each 14 square centimeters of wound)
Study NCT02813213 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard skin graft
Description: Standard split thickness (0.3-0.5mm) skin graft
Study NCT03647384 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gulingji capsules
Description: Patients take 0.6g of Gulingji capsules, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract mimetic three times a day. Treatment lasts for 24 weeks.
Study NCT03647384 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ginko Biloba Extract tablet
Description: Patients take 0.6g of Gulingji mimetic, 2 hours before breakfast, served with light salt water once a day. Also an oral take of 19.2mg Ginko Biloba Extract tablet three times a day. Treatment lasts for 24 weeks.
Study NCT04038320 — intervention group
Intervention type: DRUG
Intervention: Sofosbuvir/ledipasvir (SOF/LDV)
Description: SOF/LDV (400mg/90mg) orally once daily with or without food in the morning and will receive treatment for a duration of 12 weeks.~In addition, Ribavirin weight-based (1000 mg for patients \<75 kg and 1200 mg for those ≥75 kg) administered orally in two divided doses with food for Genotype 3 patients.
Study NCT02941848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP0816
Study NCT02941848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HGP1404
Study NCT02941848 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HCP1306
Study NCT03343210 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: quality of life and pain measurement .
Description: comparison of quality of life measurement in residents with cancer and in cancer-free residents, by a geriatric consultations'nurse
Study NCT03343210 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: quality of life and pain measurement .
Description: comparison of quality of life measurement in residents with cancer and in cancer-free residents, by a geriatric consultations'nurse
Study NCT02682004 — intervention group
Intervention type: OTHER
Intervention: leptin, serotonin and adiponectin level
Study NCT02682004 — intervention group
Intervention type: OTHER
Intervention: leptin,serotonin, adiponectin level
Study NCT02973802 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ATX-GD-59
Description: Disease specific immune modulating treatment for Graves Disease
Study NCT02361177 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Intranasal oxytocin is hypothesized to amplify the influence of social norms on unethical behavior.
Study NCT02361177 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oxytocin
Description: Intranasal oxytocin is hypothesized to amplify the influence of social norms on unethical behavior.
Study NCT04418180 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fenofibrate
Description: Patients were randomly assigned to receive oral fenofibrate 10 mg/kg/hr
Study NCT04418180 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral distilled water
Study NCT02025478 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Breastmilk
Description: * A registered dietician will supervise milk provision, and additional calories will be provided by addition of the supplement Prolacta. To make 28 kcal/oz milk, 40 ml of Prolacta will be mixed with 60 ml human milk to make a total volume of 100 ml.~* If a nursing mother enrolls on the study, maternal and not donor milk will be given in the maximum volume possible, with Prolacta supplementation if clinically indicated and recommended by the registered dietician.
Study NCT03924947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pancrelipase
Description: Delayed release capsules
Study NCT01921777 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Traumeel
Description: oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
Study NCT01921777 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral, Day 1: one tablet every 15 minutes for two hours after the exercise test, 6 hours and 10 hours after the exercise test; Day 2 and 3: two tablets thrice daily; Day 4: two tablets in the morning
Study NCT04921748 — intervention group
Intervention type: PROCEDURE
Intervention: Neurorehabilitation
Description: All patients will be treated with an in-hospital rehabilitation program focused on the rehabilitation of gait disorder in PD with 90-minute daily sessions, 6 days a week (Monday through Saturday) for four weeks. The rehabilitation treatment includes passive, active-assisted, and active exercises, isotonic and isometric exercises for the major muscles of the limbs and trunk, cardiovascular warm-up exercises, muscle stretching exercises for functional purposes, balance training exercises, specific motor exercise for hypokinesia, and 45 minutes of overground gait training delivered without devices or cueing The rehabilitation program is the same in PD patients with and without FOG.
Study NCT03713073 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Allogenic amnion chorion membrane
Description: Allogenic amnion chorion membrane (ACM) is a minimally manipulated allograft amnion chorion tissue for use as a wound covering in dental surgery.
Study NCT03713073 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Collagen dressing
Description: Collagen dressing is used to cover wounds in dental surgery.
Study NCT03892928 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group
Description: In the dexmedetomidine group, dexmedetomidine was infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. If Ramsay sedation scale score reached 3, colonoscope was inserted. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg was administrated as the rescue dose if body movement occurred during colonoscopy. In the propofol group, propofol was administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reached 3. During the whole process, propofol was given intermittently to maintain Ramsay score 3 to 4. If body movement happened, propofol 10mg was administrated every time.
Study NCT03892928 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Dexmedetomidine group
Description: In the dexmedetomidine group, dexmedetomidine was infusion intravenously with a loading dose of 0.5 μg kg-1 for 10 min, then infusion at 0.3 μg kg-1 h-1 according to the ideal body weight of the patient until the end of colonoscopy. If Ramsay sedation scale score reached 3, colonoscope was inserted. During the whole process, maintenance Ramsay score of 3 to 4. Propofol 10 mg was administrated as the rescue dose if body movement occurred during colonoscopy. In the propofol group, propofol was administrated 1 mg kg-1 intravenously, then titrated given by 0.5 mg kg-1 until Ramsay score reached 3. During the whole process, propofol was given intermittently to maintain Ramsay score 3 to 4. If body movement happened, propofol 10mg was administrated every time.
Study NCT04221022 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Light physical activity
Description: Each session started with leisure walk, duration of which was set to 35 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
Study NCT04221022 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Moderate physical activity
Description: Each session started with brisk walk, duration of which was set to 30 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
Study NCT04221022 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Vigorous physical activity
Description: Each session started with jogging, duration of which was set to 15 minutes. Frequency set for the session was that each individual of the group had to walk for five days a week for total of six weeks. (total 30 days in six weeks)
Study NCT00630591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standardized Materials Group
Description: 7 sets of print materials will be mailed every 6-7 weeks. A short survey about the information received and how useful it was will be completed.
Study NCT00630591 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Independent Tailored Intervention
Description: Personalized notebooks and newsletters of diet and exercise information will be mailed. A short survey about the information received and how useful it was will be completed.
Study NCT03227978 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: PCL mesh pleurodesis
Description: Coverage of the lung surface by PCL mesh
Study NCT03009019 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DFN-15 Active
Study NCT03009019 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: DFN-15 Placebo
Study NCT02194842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ra223
Study NCT02194842 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enzalutamide
Study NCT02194842 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enzalutamide
Study NCT00808145 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine / Cisplatin / Sorafenib
Description: All patients will receive gemcitabine 1000mg/m2 cisplatin 30mg/m2 sorafenib 400mg orally twice daily
Study NCT01522677 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PDT with 5-ALA radiosensitization
Description: Patients receive neoadjuvant PDT with radiosensitizing 5-ALA 4 days prior to surgery for colon cancer.
Study NCT04205955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive healthy living education via phone call
Study NCT04205955 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Dietary Intervention
Description: Receive diet modification coaching via phone call
Study NCT04205955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Message
Description: Receive motivational messages via email and/or text message
Study NCT04205955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Message
Description: Receive motivational messages via email and/or text message
Study NCT04205955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04205955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04205955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT04205955 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT01836016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salbutamol (Ventolin®)
Description: According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salbutamol was used to Group A patients for 26 weeks: Salbutamol (Ventolin®, GlaxoSmithKline) 100μg/dose, 200 inhalations. 100 μg each time (when needed), and the maximum dose is 8-12 inhalations a day.
Study NCT01836016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Formoterol (Oxis Turbuhaler®)
Description: According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Formoterol was used to Group B patients for 26 weeks: Formoterol (Oxis Turbuhaler®, AstraZeneca), 4.5μg/ dose, 60 inhalations. 4.5μg each time, twice daily.
Study NCT01836016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Salmeterol / fluticasone (Seretide®)
Description: According to the revised 2011 GOLD, patients will be divided into Group A, B, C, and D based on individualized assessment. Salmeterol / fluticasone was used to Group C patients and Group D patients for 26 weeks: Salmeterol / fluticasone (Seretide®, GlaxoSmithKline), 50/500 μg / dose, 60 inhalations. 50/500 μg each time, twice daily.
Study NCT01836016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufei granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of lung-qi deficiency will be given Bufei granule, twice daily for 26 weeks for lower dosage.
Study NCT01836016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufeijianpi granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of deficiency of pulmonic-splenic qi will be given Bufeijianpi granule, twice daily for 26 weeks for lower dosage.
Study NCT01836016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bufeiyishen granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi of the lung and kidney will be given Bufeiyishen granule, twice daily for 26 weeks for lower dosage.
Study NCT01836016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yiqizishen granule
Description: According to traditional Chinese syndrome differentiation and treatment, patients with syndrome of insufficiency of qi and yin of the lung and kidney will be given Yiqizishen granule, twice daily for 26 weeks for lower dosage.
Study NCT01836016 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: conventional medicine + TCM
Description: Patients will be given the combination of conventional medicine (Salbutamol, Formoterol, Salmeterol / fluticasone, Salmeterol / fluticasone) and (Bufei granule, Bufeijianpi granule, Bufeiyishen granule and Yiqizishen granule) for 26 weeks.
Study NCT01396200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine
Description: Dose level 1: 800mg by mouth daily Dose level -1: 600 mg by mouth daily
Study NCT01396200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rapamycin
Description: Dose level 1: Loading dose 12mg, daily dose 4mg Dose level -1: Loading dose 9mg,daily dose 3mg
Study NCT04567797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laevo 2
Description: The Laevo V2 is a wearable chest and back support exoskeleton. The Laevo transfers the from its chest pad to the thighs while bending forward. The passive exoskeleton (works with gas springs, not motors) transfers part of the load away from the back muscles, reducing the pressure on the spinal column. It provides a dampening effect on the back, reducing the risk of sudden back muscle contractions that needlessly overcompress the spine.
Study NCT04567797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: backX
Description: backX is a novel industrial exoskeleton that substantially augments its wearer and reduces the forces and torques on a wearer's lower back region (L5/S1 disc) by an average of 60% while the wearer is stooping, lifting objects, bending or reaching. backX augments the wearer's strength and can reduce the risk of back injuries among workers. It does not require external motors or power source. The mechanism of backX is similar to the first device Laevo 2.
Study NCT04567797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FLx ErgoSkeleton
Description: The FLx ErgoSkeleton is a range limiting work vest for physical work use. The FLx naturally reminds the user of the correct posture and lifting techniques while on the job site.
Study NCT04567797 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V22 ErgoSkeleton
Description: Similar to the FLx ErgoSkeleton, the V22 ErgoSkeleton keeps the position of the human body as to always stay within a safe body posture while lifting or moving heavy objects. The V22 ErgoSkeleton applies pressure to remind the user both during improper lifts and over rotation.~In addition, the V22 ErgoSkeleton comes with two clutch controlled cables to assist in lifting and moving. The cables transfer part of the weight of the object being held directly to the V22 ErgoSkeleton vest, similar to other arm and shoulder support exoskeletons.
Study NCT04747210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: contextual one-on-one coaching
Description: Training workshop and coaching one-on-one
Study NCT04747210 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Trainig workshop
Description: Ten-hour training workshop.
Study NCT00616577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine
Description: caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
Study NCT00616577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: caudal ropivacaine 0.25% at a dose of 1ml/kg (maximum 15ml) with 1:200,000 epinephrine
Study NCT00616577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine
Description: local infiltration of ropivacaine 0.25% up to 1ml/kg (maximum 15ml) around the surgery site
Study NCT03396211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Apatinib
Description: Apatinib tablets
Study NCT03396211 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Fixed dose of nivolumab given intravenously every 2 weeks